Article Details
Retrieved on: 2024-07-12 20:13:39
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer's push into obesity will be led by a once-daily formulation of GLP-1 agonist danuglipron as it tries to catch up with Novo Nordisk and Eli ...
Article found on: pharmaphorum.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here